SMT201700043B - Formulazioni di bendamustina - Google Patents

Formulazioni di bendamustina

Info

Publication number
SMT201700043B
SMT201700043B SM201700043T SM201700043T SMT201700043B SM T201700043 B SMT201700043 B SM T201700043B SM 201700043 T SM201700043 T SM 201700043T SM 201700043 T SM201700043 T SM 201700043T SM T201700043 B SMT201700043 B SM T201700043B
Authority
SM
San Marino
Prior art keywords
bendamustine formulations
bendamustine
formulations
Prior art date
Application number
SM201700043T
Other languages
English (en)
Inventor
Nagesh R Palepu
Philip Christopher Buxton
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44309429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201700043(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of SMT201700043B publication Critical patent/SMT201700043B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM201700043T 2010-01-28 2017-01-20 Formulazioni di bendamustina SMT201700043B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29910010P 2010-01-28 2010-01-28
PCT/US2011/022958 WO2011094565A1 (en) 2010-01-28 2011-01-28 Formulations of bendamustine

Publications (1)

Publication Number Publication Date
SMT201700043B true SMT201700043B (it) 2017-03-08

Family

ID=44309429

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201700043T SMT201700043B (it) 2010-01-28 2017-01-20 Formulazioni di bendamustina

Country Status (16)

Country Link
US (12) US8609707B2 (it)
EP (3) EP2528602B2 (it)
JP (2) JP5795600B2 (it)
CA (1) CA2787568C (it)
CY (2) CY1118769T1 (it)
DK (2) DK3158991T3 (it)
ES (2) ES2609106T5 (it)
HR (2) HRP20161771T4 (it)
HU (2) HUE054836T2 (it)
LT (2) LT2528602T (it)
PL (2) PL2528602T5 (it)
PT (2) PT3158991T (it)
RS (2) RS62327B1 (it)
SI (2) SI2528602T2 (it)
SM (1) SMT201700043B (it)
WO (1) WO2011094565A1 (it)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054836T2 (hu) 2010-01-28 2021-10-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelései
EP2675460A4 (en) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc TREATMENT OF FAT TISSUE UNDER CHIN
WO2013112762A1 (en) * 2012-01-24 2013-08-01 Innopharma, Inc. Bendamustine compositions and methods therefore
EP2814487A4 (en) * 2012-02-14 2015-07-15 Eagle Pharmaceuticals Inc BENDAMUSTIN FORMULATIONS
CA2867343C (en) * 2012-03-20 2020-08-11 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
WO2013142358A1 (en) * 2012-03-20 2013-09-26 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
CN105491886B (zh) 2013-08-27 2019-01-29 V·沃道里斯 苯达莫司汀医药组合物
EP3047850A4 (en) * 2013-09-20 2017-05-10 Santen Pharmaceutical Co., Ltd Polyethylene glycol-containing composition
US20160235717A1 (en) * 2013-10-11 2016-08-18 Luitpold Pharmaceuticals, Inc. Bendamustine pharmaceutical compositions
CN115350155A (zh) 2014-03-13 2022-11-18 V·沃道里斯 苯达莫司汀固体分散体和连续输液
WO2016005995A2 (en) * 2014-07-10 2016-01-14 Leiutis Pharmaceuticals Pvt. Ltd. Glycol free stable liquid compositions of bendamustine
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
WO2017079700A1 (en) * 2015-11-04 2017-05-11 Kythera Biopharmaceuticals, Inc. Treatments of accumulated fat with deoxycholic acid and salts thereof
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
KR20200136997A (ko) * 2018-03-29 2020-12-08 프로젝트 파마슈틱스 게엠베하 액체 약학적 제형
JP2021534253A (ja) 2018-08-17 2021-12-09 ホスピーラ オーストラリア ピーティーワイ リミテッド 液体ベンダムスチン医薬組成物
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
JP2020090481A (ja) * 2018-11-27 2020-06-11 日本化薬株式会社 ベンダムスチンを含有する溶液製剤
JP7235288B2 (ja) * 2019-01-07 2023-03-08 コーアイセイ株式会社 ベンダムスチンの液体製剤
WO2020170104A1 (en) * 2019-02-18 2020-08-27 Shilpa Medicare Limited Liquid bendamustine parenteral compositions
WO2021161876A1 (ja) * 2020-02-10 2021-08-19 富士フイルム株式会社 ベンダムスチン液剤
WO2023067188A1 (en) 2021-10-22 2023-04-27 Project Pharmaceutics Gmbh Liquid pharmaceutical formulation
GB202118175D0 (en) 2021-12-15 2022-01-26 Arecor Ltd Novel composition
US11707450B1 (en) 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (it) * 1903-10-08 1905-03-16
DE80967C (it)
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
DD152989A1 (de) 1980-09-11 1981-12-16 Klaus Kunze Anordnung zur korrektur von soll-und istwerten
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de) * 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
AU688792B2 (en) 1993-10-27 1998-03-19 Pharmacia & Upjohn Company Stabilized prostaglandin e1
WO1995019759A1 (en) * 1994-01-24 1995-07-27 The Procter & Gamble Company Process for solubilizing difficultly soluble pharmaceutical actives
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
WO1999001118A2 (en) 1997-07-01 1999-01-14 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
US20020039597A1 (en) * 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
CA2412849A1 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
EP1296678A2 (en) 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
WO2001097860A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
EP1311301A2 (en) 2000-07-06 2003-05-21 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions and methods for preparation thereof
AU2001211213A1 (en) 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
CA2493878C (en) * 2002-07-30 2013-07-23 Wyeth Parenteral formulations containing a rapamycin hydroxyester
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
EP1814544A4 (en) 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
JP2008520652A (ja) 2004-11-22 2008-06-19 ヴィーナス・レメディーズ・リミテッド 非水性液状の非経口的アセクロフェナク製剤
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US20080200383A1 (en) 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN1850048A (zh) 2006-06-09 2006-10-25 山东蓝金生物工程有限公司 一种含血管抑制剂的抗癌缓释注射剂
JPWO2008020584A1 (ja) 2006-08-14 2010-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定な凍結乾燥製剤
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
DE102007003184A1 (de) 2007-01-22 2008-07-24 Orlowski, Michael, Dr. Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en) 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CA2735899A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
WO2010083276A1 (en) 2009-01-15 2010-07-22 Cephalon, Inc. Novel forms of bendamustine free base
CA2753641C (en) 2009-02-25 2014-09-16 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
CA2760085A1 (en) 2009-04-28 2010-11-04 Cephalon, Inc. Oral formulations of bendamustine
WO2010148288A2 (en) 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
CN101584668A (zh) 2009-06-19 2009-11-25 江苏奥赛康药业有限公司 盐酸苯达莫司汀冻干粉针剂
US8389558B2 (en) 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US20110015245A1 (en) 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US7772274B1 (en) * 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
HUE054836T2 (hu) 2010-01-28 2021-10-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelései
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013540104A (ja) 2010-07-28 2013-10-31 イーグル・ファーマシューティカルズ・インコーポレーテッド 延長された保存安定性を有するペメトレキセドを含有する医薬組成物
EP2635558A4 (en) 2010-11-01 2014-08-06 Shilpa Medicare Ltd PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
CA2838387A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
JP6483442B2 (ja) 2011-12-05 2019-03-13 エックス−ボディ インコーポレイテッド Ｐｄｇｆ受容体ベータ結合ポリペプチド
JP6148250B2 (ja) 2011-12-05 2017-06-14 バイオ−ラッド ラボラトリーズ，インコーポレイティド 組換え脱アミド化グリアジン抗原
WO2013112762A1 (en) 2012-01-24 2013-08-01 Innopharma, Inc. Bendamustine compositions and methods therefore
EP2814487A4 (en) 2012-02-14 2015-07-15 Eagle Pharmaceuticals Inc BENDAMUSTIN FORMULATIONS
CA2867343C (en) 2012-03-20 2020-08-11 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
WO2013142358A1 (en) 2012-03-20 2013-09-26 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
JP6331468B2 (ja) 2014-02-27 2018-05-30 住友ベークライト株式会社 金属ラミネート用フィルム、ラミネート金属板および金属容器
US11707450B1 (en) * 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Also Published As

Publication number Publication date
RS55491B2 (sr) 2020-11-30
JP2013518130A (ja) 2013-05-20
RS62327B1 (sr) 2021-10-29
ES2609106T3 (es) 2017-04-18
PL2528602T3 (pl) 2017-03-31
DK3158991T3 (da) 2021-06-14
US20230115164A1 (en) 2023-04-13
CY1118769T1 (el) 2017-07-12
CA2787568C (en) 2019-04-02
US20140024691A1 (en) 2014-01-23
US20190350904A1 (en) 2019-11-21
EP2528602B2 (en) 2020-02-12
ES2875374T3 (es) 2021-11-10
US9572796B2 (en) 2017-02-21
US20240075013A1 (en) 2024-03-07
EP2528602A1 (en) 2012-12-05
HUE054836T2 (hu) 2021-10-28
US9572797B2 (en) 2017-02-21
SI2528602T1 (sl) 2017-03-31
US20230115693A1 (en) 2023-04-13
HRP20161771T4 (hr) 2020-08-07
SI2528602T2 (sl) 2020-10-30
US11872214B2 (en) 2024-01-16
US11103483B2 (en) 2021-08-31
HRP20161771T1 (hr) 2017-02-24
CY1124262T1 (el) 2022-07-22
JP5795600B2 (ja) 2015-10-14
HRP20210915T1 (hr) 2021-10-01
US20160143888A1 (en) 2016-05-26
US10010533B2 (en) 2018-07-03
WO2011094565A1 (en) 2011-08-04
ES2609106T5 (es) 2020-11-10
US20180296535A1 (en) 2018-10-18
HUE031208T2 (hu) 2017-07-28
US20160143887A1 (en) 2016-05-26
US20210393594A1 (en) 2021-12-23
PT2528602T (pt) 2017-01-12
DK2528602T4 (da) 2020-04-27
PT3158991T (pt) 2021-06-23
US20180296536A1 (en) 2018-10-18
PL2528602T5 (pl) 2020-09-07
JP2016020365A (ja) 2016-02-04
EP3895694A1 (en) 2021-10-20
PL3158991T3 (pl) 2021-09-27
EP3158991A1 (en) 2017-04-26
DK2528602T3 (en) 2017-01-23
US20110184036A1 (en) 2011-07-28
US8609707B2 (en) 2013-12-17
EP3158991B1 (en) 2021-03-17
LT2528602T (lt) 2017-02-27
US11844783B2 (en) 2023-12-19
US20180000789A1 (en) 2018-01-04
EP2528602A4 (en) 2014-01-22
SI3158991T1 (sl) 2021-10-29
CA2787568A1 (en) 2011-08-04
LT3158991T (lt) 2021-07-12
US9265831B2 (en) 2016-02-23
JP6133943B2 (ja) 2017-05-24
EP2528602B1 (en) 2016-10-05
RS55491B1 (sr) 2017-04-28

Similar Documents

Publication Publication Date Title
SMT201700043B (it) Formulazioni di bendamustina
SMT201600049B (it) Formulazioni di apixaban
DK3170508T3 (da) Vaccineformuleringer
BR112012028556A2 (pt) Indóis
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
DE112011104226A5 (de) Käfigmutter
FIU20114054U0 (fi) Dieettiformulaatiot
GT201200303A (es) Formulaciones farmacéuticas
DK3072505T3 (da) Testosteronformuleringer
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
BRPI1009465A2 (pt) Formulação
DE112011101226A5 (de) Linearwegmesssystem
DE112011102080A5 (de) Kupplungszentralausrücker
ZA201306016B (en) Bendamustine formulations
DK2442899T3 (da) Rotorskive
DE102011002623A8 (de) Ventilsteuerzeitversteller
DE112011102711A5 (de) Hydrostataktor
DK2448659T3 (da) Rotorskive
DK2447426T3 (da) Vaske-WC
DE102010019119B8 (de) Cuttermesser
DE112010005518A5 (de) Dichtungsmanchette
DE102010038420A8 (de) Reinigungungsvorrichtung
BR112013001462A2 (pt) composições de ciclopolissacarídeos aniônico-catiônicos de bendamustina
CO6801789A2 (es) N-hetarilmetil pirazolilcarboxamidas